Objective The rationale for this project is given by the fact that the pharmaceutical industry is currently undergoing a significant change in strategy in preclinical drug development. Relevant advances are being made in the field of genome analysis with the onset of gene chip technologies permitting high throughput investigations and the use of miniature sample quantities. The same is happening for protease analysis and mass- spectrometry. We want to develop the "missing link" in high throughput testing: A highly controlled high-throughput bioreactor based on the use of engineered miniature in vitro tissue analogues. This will lead to the establishment of a firm correlation between genome, protease and catalytic expressions or biochemical function resulting in a complementary and more predictive picture of drug action. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoveryengineering and technologyenvironmental biotechnologybioremediationbioreactorsnatural scienceschemical sciencesanalytical chemistrymass spectrometrysocial scienceseconomics and businesseconomicssustainable economynatural sciencesbiological sciencesgeneticsgenomes Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-5. - Key action Sustainable Agriculture, Fisheries and Forestry Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY EU contribution No data Address NTNU 7491 TRONDHEIM Norway See on map Total cost No data Participants (2) Sort alphabetically Sort by EU Contribution Expand all Collapse all AACHEN UNIVERSITY OF TECHNOLOGY Germany EU contribution No data Address Eilfshornstrasse, 16 52056 AACHEN See on map Total cost No data CENTRE FOR RURAL RESEARCH Norway EU contribution No data Address University Centre, NTNU Dragvoll 7491 TRONDHEIM See on map Total cost No data